Clinical trials: Ejection Fraction
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack.
- Trial name
- NCT00684060
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- The University of Texas Health Science Center, Houston
Iron Deficiency (ID), Heart Failure
Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure
The INITIATE-HF study is a cluster randomized controlled trial that aims to find out if reminding doctors about treatment guidelines for iron deficiency in adults with heart failure who are hospitalized and have evidence of iron…
- Conditions
- Iron Deficiency (ID), Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- INITIATE-HF (NCT07467668)
- Testing
- Notification Group, No Notification Group
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Kaiser Permanente
CABG in Low EF
Early Outcome in Unstable Angina Patients With Low EF After CABG
Coronary artery bypass grafting (CABG) among patients with reduced myocardial function remains a surgical challenge despite improvement in surgical technique, myocardial protection and postoperative care.
- Trial name
- NCT03276624
- Testing
- CABG
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Telemonitoring of HFrEF Patients
The aim of this study is to find out whether remote health monitoring can help people with chronic heart failure. For 3 months, some patients use a SiDLY CARE PRO electronic wristband.
- Trial name
- NCT07835490
- Testing
- Telemonitoring wristband
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Lodz
Coronary Artery Disease, Diabetes Mellitus, Type 2
The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes
The purpose of this study is to investigate the effect of combined glucagon-like-peptide-1 (GLP-1) analogue and metformin therapy on glucose metabolic and cardiovascular endpoints compared to metformin monotherapy in patients…
- Trial name
- AddHope2 (NCT01595789)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 41 people
- Sponsor
- Haugaard, Steen Bendix, M.D., DMSc
Cardiovascular Disease
A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
The Sponsor is developing the test medicine, AZD4831, for the potential treatment of cardiovascular disease (CVD). CVD is a general term to describe a range of conditions that affect the heart and blood vessels, examples of CVD…
- Trial name
- NCT04407091
- Testing
- 14C]AZD4831 Oral Solution
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Diabetes Mellitus, Heart Failure
Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily.
- Trial name
- NCT06915870
- Testing
- Dapagliflozin 10 mg daily, Empagliflozin 10 MG OD
- Where
- Pakistan
- Volunteers
- 108 people
- Sponsor
- Fatima Maqsood
Heart Failure With Reduced Ejection Fraction NYHA Class III-IV
Beta 3 Agonist Treatment in Heart Failure-2
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to severe chronic heart failure (LVEF<35%, NYHA…
- Trial name
- BEAT-HF II (NCT03926754)
- Testing
- Mirabegron
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Henning Bundgaard
Atrial Fibrillation, Ivabradine
Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Previous studies have shown that rate control strategy in AF is non-inferior to rhythm control strategy, in terms of stroke and mortality…
- Conditions
- Atrial Fibrillation, Ivabradine, Heart Failure
- Trial name
- NCT04308031
- Testing
- Ivabradine 5 mg [Corlanor], Digoxin 0.25 mg
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chun-Yao Huang
Heart Failure
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant…
- Trial name
- HFpEF (NCT02876042)
- Testing
- BAROSTIM NEO™ System
- Where
- 13 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CVRx, Inc.
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Right Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction
Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction. The Study Tests the Superiority of Right Ventricular Bifocal Stimulation Over VVI Implantable Defibrillator in Right Bundle Branch Block and Heart Failure.
RATIONALE: Cardiac resynchronization therapy (CRT) is known to improve cardiac performance and to reduce morbidity and mortality in reduced-ejection fraction heart failure (HFrEF) despite optimal medical therapy (OMT).
- Conditions
- Right Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction, Bifocal Stimulation
- Trial name
- BiPARK-HF (NCT03524001)
- Testing
- Compare VVi mode versus DDD bifocal stimulation through crossover randomization
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States.
- Trial name
- FIRE-HFpEF (NCT05839730)
- Testing
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction, Ventricular Arrhythmia
Circulating RNA Markers of Ventricular Arrhythmias in Remotely Monitored Patients With Post-Infarction Heart Failure and Implanted Cardioverter-Defibrillators
This prospective observational study evaluates whether circulating small non-coding RNAs, particularly microRNAs, are associated with ventricular arrhythmias in patients with post-myocardial infarction heart failure who have an…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Ventricular Arrhythmia, Ischemic Cardiomyopathy
- Trial name
- NCT07795892
- Testing
- Circulating Small RNA Profiling
- Where
- Poland
- Volunteers
- 57 people
- Sponsor
- University of Rzeszow
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication
This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Conduction Disorder
- Trial name
- ESCPAND (NCT06278844)
- Testing
- Conduction system pacing, Right ventricular apical pacing
- Where
- Belgium
- Volunteers
- 75 people
- Sponsor
- University Hospital, Antwerp
Heart Failure
Alleviant ALLAY-HFrEF Study
Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in…
- Trial name
- NCT06812533
- Testing
- Alleviant ALV1 System
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 350 people
- Sponsor
- Alleviant Medical, Inc.
Ventricular Ejection Fraction
DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function
The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when…
- Trial name
- NCT00401687
- Testing
- Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- 10 sites in United States
- Volunteers
- 131 people
- Sponsor
- Lantheus Medical Imaging
Heart Failure With Preserved Ejection Fraction
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
- Trial name
- NCT05322616
- Testing
- JK07
- Where
- 7 sites in United States
- Sponsor
- Salubris Biotherapeutics Inc
Diastolic Dysfunction
Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Diastolic Dysfunction
Although half of the patients with HF has normal ejection fraction or slightly altered (HF-PEF) and the prognosis differs little from those with reduced ejection fraction, the pathophysiology of HF-PEF is still poorly understood.
- Trial name
- NCT01896908
- Testing
- Sodium restriction
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.